瑞迪博士实验室 RDY

Mr. Erez Israeli is Chief Executive Officer of our company and prior to that he was our Chief Operating Officer and the Global Head of Generics and PSAI business. He joined us in 2018. With over 32 years of experience in the pharmaceutical industry, Mr. Israeli is an accomplished leader with a proven track record of achievement. Prior to joining us, Mr. Israeli was President and Chief Executive Officer of Enzymotec. Prior to that, he spent 23 years working at Teva Pharmaceutical Industries Limited (Teva), where he held several leadership positions in the API and pharmaceutical (Generics, Specialty and OTC) businesses. His positions of responsibility included Vice President Marketing & Sales for North America, Vice President Asia Operations, President of Teva API, Group Executive Vice President, Head of Global Quality, and President & CEO of Growth Markets. He was also the Head of the Global Quality function for Teva and has held Board positions at subsidiaries of Teva. He graduated from Bar Ilan University in Israel, majoring in art, economics and business administration, and received an MBA in Finance and Marketing from Bar Ilan University. Under Mr. Israeli leadership, our company has seen significant growth in both revenue and profitability. Our company has concluded acquisitions of key assets in India and internationally as well as launched several first-to-market products. Mr. Israeli has also steered us through our pandemic response, ensuring that commitments to supply medicines to patients and to employees' safety are met. Under Mr. Israeli's guidance, we have also broken new ground on digitalization across Research & Development, Manufacturing and Sales - along with our focus on innovation, this will yield significant dividends in the years to come.

Mr. G.V. Prasad holds a graduate degree in Industrial Administration from Purdue University and an undergraduate degree in Chemical Engineering from the Illinois Institute of Technology, Chicago. He has been associated with Dr. Reddy's since 1986 as a Board Member and has been in a full-time executive role since 1990. Under his leadership, Dr. Reddy's has evolved from a midsized domestic enterprise into a diversified and trusted global pharmaceutical company, with revenues of nearly U.S.$3.6 billion in the year ended March 31, 2026. Mr. Prasad strongly emphasizes Deep Science, Good Governance, Progressive People Practices, and Sustainability, and actively mentors leaders to help them realize their full potential while contributing meaningfully to society. He is deeply engaged in social and environmental initiatives and is actively involved with non-governmental organizations such as Aakar Asha Trust, which operates a free hospital providing corrective surgeries for children with deformities, and the World Wide Fund for Nature (WWF), Telangana Chapter. He also serves as a Board Member of the Indian School of Business (ISB). Mr. Prasad has been serving as the Honorary Consul of the Kingdom of Belgium in Hyderabad since April 2019, contributing to the strengthening of bilateral economic, academic, and cultural ties between Belgium and India. Outside of his professional commitments, he is a photography enthusiast, avid birdwatcher, and keen traveller, with a particular interest in wilderness destinations. In recognition of his leadership and impact, Mr. Prasad was named among the Top 50 CEOs India Has Ever Had by Outlook magazine in 2017 and was recognized as one of the Top 5 Most Valuable CEOs of India by Businessworld in 2016. He was also featured in the Medicine Maker 2018 Power List of influential professionals shaping the future of drug development and was named India Business Leader of the Year by CNBC Asia in 2014 and 2015.

The designation of Mr. Patrick Aghanian has changed from Chief Executive Officer, Europe Generics to Head - Consumer Health Organization, effective from April 1, 2026. Mr. Patrick Aghanian serves as Head of Generics, Europe, and Head of Consumer Health. He has been with us since 2019, and has worked in pharmaceuticals for 30 years. He started his career with Glaxo SmithKline Consumer Health, where he held various General Management positions for 8 years. He then moved to the prescription business, when he joined Novartis Pharma. After 5 years with Novartis, he joined Sanofi, where he held various senior General Management and regional head roles for 10 years. His last assignment with Sanofi was to divest the European generic business in October 2018, now known as Zentiva. Mr. Aghanian has experience spanning originator, consumer health and generic pharmaceuticals, including specialist fields such as Oncology, Diabetes and rare diseases. Patrick earned his Master of Business Administration (MBA) from the UCLA Anderson School of Management/University of California, Los Angeles and holds a Bachelor of Arts from the University of California, Los Angeles.

Mr. K. Satish Reddy is the Chairman of our company. He joined us in 1993 and since then has held positions of increasing responsibility. He led the organization's transition from a uni-focused manufacturer of active pharmaceutical ingredients (API) to a company that moved up the value-chain with a diverse product portfolio of Finished Dosage Formulations. He oversaw the expansion and establishing of a strong footprint for finished dosage products in Russia, China and other emerging markets. As an active member of various major pharmaceutical industry associations and governmental panels, Mr. K. Satish Reddy plays a key role in shaping policies concerning the pharmaceutical sector that include India's patent law, drug pricing and important amendments to India's Drugs & Cosmetics Act. He is the Member of the Confederation of Indian Industry (CII) Governing Council and a Member of the International Generic and Biosimilar Medicines Association (IGBA) CEO Advisory Committee. He also plays a key role in shaping skill development in India. Mr. K. Satish Reddy is the governing board member of the Young India Skill University and in the past, he was the Chairman of the Life Sciences Skill Development Council under The National Skill Development Corporation (NSDC), an organization, working in partnership with various stakeholder groups, to serve and address the skill shortfalls in the life sciences sector across India. He has also led various National Committees on the India G20 Presidency for 2023. He was the President of the Indian Pharmaceutical Alliance, a premier industry association of leading research based Indian companies from 2019-2021 and 2013-2015. He was the Chairman of the Board of Governors of the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad. He was a member of the Drugs Technical Advisory Board of India, the Chairman of the Andhra Pradesh Chapter of the CII and head of its National Committee on Pharmaceuticals. In May 2015, the Ministry of Labour and Employment, Government of India, nominated him as Chairman of the Board of Governors of the National Safety Council. Keeping true to the legacy of the founder of our company, Dr. Anji Reddy, he drives our Corporate Social Responsibility initiatives. The Dr. Reddy's Foundation, of which Mr. K. Satish Reddy is Chairman, works to help the less privileged create sustainable livelihoods through appropriate vocational education. He is a Trustee of the Naandi Foundation, which works in the areas of child rights and education, safe drinking water, agriculture export marketing support and other much needed empowerment initiatives that India need. He is also one of the Directors of Dr. Reddy's Institute of Life Sciences, the not-for-profit institute engaged in pioneering and innovative research in unifying areas of chemistry, biology and chemical biology. Mr. K. Satish Reddy was identified as a Young Global Leader for 2007 by the World Economic Forum, and was presented with the IBLA - India Corporate Citizen of the Year award by CNBC in 2005 for his contributions to Corporate Social Responsibility. He holds a degree in Chemical Engineering from Osmania University, India, and an M.S. in Medicinal Chemistry from Purdue University, USA, where he received the 2009 Distinguished Alumnus Award from the School of Pharmacy and Pharmaceutical Sciences.

Mr. M.V. Ramana is our Chief Executive Officer, Global Generics and leads innovation for our company. In this role, he leads a multicultural team in 45 countries. A passionate believer in the organization's purpose of accelerating access to innovative and affordable healthcare, Mr. Ramana has spearheaded our company's foray into several new markets and spaces and has secured its position as an established generics leader in them. He is also a member of the Management Council of our company. As the CEO of Branded Markets, Mr. Ramana is responsible for dealing with complex, ambiguous business environments which present a huge growth potential. In doing so, Mr. Ramana has been able to think ahead and build robust strategies which have delivered market beating growth in their respective spaces. Not only has he been able to push the envelope on new therapy areas, but has also built new age skills in the space of sales, marketing and portfolio building. Mr. Ramana has demonstrated ambidexterity and an appetite for risk as he spearheads disruptive spaces, navigating new business models and leveraging both deep science and technology platforms. Leading multiple workstreams across business units and geographies, he is currently engaged in building the Innovative Products side of the business across our company. Mr. Ramana joined us as a Management Trainee in 1992 in the International Marketing division of our Branded Formulations business. Since then, he has handled various critical assignments such as setting up the business in several countries across Asia, Latin America, Africa Russia, and the Middle East, as well as our joint venture in China. He holds an MBA from Osmania University, Hyderabad and is a graduate of the ISB-Kellogg management development program.

Mr. Milan Kalawadia serves as Chief Executive Officer, North America, and is based out of our Princeton, New Jersey office. He is responsible for leading our North America business and serves as a member of the Board of Dr. Reddy's Laboratories, Inc. Mr. Kalawadia is an accomplished senior executive, having served our company in various positions of increasing responsibility for more than 20 years. Prior to his appointment as CEO-North America, Mr. Kalawadia served as Chief Commercial Officer-North America, responsible for the customer-facing and commercialization operations for the three main verticals of the core North America business: retail Rx, hospital/institutional injectable, and private label OTC. Mr. Kalawadia's efforts as Chief Commercial Officer-North America were instrumental in driving our North America business to three consecutive years of growth over the $1 billion revenue threshold. He led the early efforts to develop strategies for our Biosimilars and Self-care & Wellness business units in the United States. He also played a critical role in driving various new growth initiatives, including the acquisition of over-the-counter brands; the development of our e-commerce presence on Amazon; and engaging with alternate channel partners. Mr. Kalawadia holds a Bachelor of Science degree in Management Science and Information Systems from Rutgers University, School of Business; and a Master of Business Administration degree from Carnegie Mellon University, Tepper School of Business.

Mr. M.V. Narasimham serves as the Chief Financial Officer of our company. With a distinguished career spanning over three decades, he brings a wealth of expertise and strategic insights to the role. He is a Chartered Accountant by qualification and has held various pivotal positions within our company since joining in 2000. In his previous capacity as Deputy Chief Financial Officer of the company, he was responsible for global commercial business finance and global taxation, overseeing critical financial functions that spanned across geographies. His leadership was instrumental in steering the financial operations of our Pharmaceutical Services and Active Ingredients (PSAI) and Global Generics segments from 2006 to 2012. Under his stewardship, these businesses experienced significant growth and operational efficiencies. Since 2012, Mr. Narasimham has been at the helm of Corporate Finance, managing crucial areas such as Direct and Indirect Taxation, Consolidation, and Corporate Analytics. His role extended beyond traditional finance, encompassing the comprehensive management of our Global Business finance, including both India and international operations. His deep understanding of complex financial landscapes and his commitment to excellence have consistently driven our company's financial strategy and performance.

The designation of Mr. Sanjay Sharma has changed from Global Head Operations and Chief Human Resources Officer (CHRO) to Chief Operating Officer, effective from April 1, 2026. Mr. Sanjay Sharma is our Chief Operations Officer. He is a transformational leader with close to 35 years in the fast moving consumer goods and pharmaceuticals industries, handling a diverse set of roles spanning across Manufacturing, Supply Chain, Procurement, Sales, Portfolio Management and Environmental, Social and Governance (ESG) functions in both emerging and developed markets. In his present role, he is our head of Global Manufacturing Operations and leads our Product Selection to Commercialization, end-to-end Operations and ESG . He also handles the responsibility of Chief Human Resources Officer (CHRO). Prior to joining our company, he worked with Hindustan Coca-Cola as a Whole Time Director, where he led their Integrated Supply Chain Operations for India and South Asia. Sanjay holds a bachelor's degree in Chemical Engineering from IIT Delhi, and General Management from IIM Ahmedabad. He recently completed the Advanced Management Program (AMP) at Harvard Business School.

Mr. Deepak Sapra is the Chief Executive Officer of API and Services. As part of his role, he heads our API business, the Aurigene Pharmaceutical Services Limited (APSL) business, public health initiatives and business-to-business collaborations for our company. Mr. Sapra joined our company in 2003 from the Indian Institute of Management (IIM), Bangalore and has since then undertaken various roles in Marketing, Sales, Business Development and Portfolio covering most markets around the world. He also led our COVID initiatives on therapeutics as well as on vaccines. Mr. Sapra's education is in engineering and management. Prior to joining our company, he worked in the Indian Railway Services, Government of India. He has also been a Fulbright fellow and a Chevening scholar. He is a published author and his first book was published in 2018. He is also the co-founder of a charitable trust that works for people with disabilities in eastern India.

Mr. Krishna Venkatesh serves as our Global Head of the Integrated Product Development Organization (IPDO). With over 29 years of experience in the pharmaceutical industry, he brings deep expertise across product development, process engineering, technology transfer, quality, and manufacturing operations. Mr. Venkatesh is passionate about building and enabling high-performing management teams to drive sustainable business growth and operational excellence. He remains strongly committed to delivering long-term value through innovation, collaboration, and disciplined execution. Over the course of his distinguished career, he has worked with leading global pharmaceutical organizations, including Barr Pharmaceuticals and Teva Pharmaceuticals in the United States. Mr. Venkatesh is a graduate of the General Management Program at Harvard Business School. He holds a Master's degree in Pharmaceutical Sciences from the University of Mississippi and a Bachelor of Pharmacy (B.Pharm) from BITS Pilani.

Mr. Phanimitra B. serves as the Chief Digital and Information Officer of our company. In this role, he has global responsibility for Digital Transformation, Process Excellence and Information Technology Management of our company. Mr. Phanimitra joined our company in 2014 and played various roles - setting up the Analytics Centre of Excellence, leading corporate strategy and digital transformation for Dr. Reddy's India and our Emerging Markets businesses. Before joining our company, he worked with Hewlett Packard for over 11 years with roles in strategy, analytics & transformation consulting for customers across industries in the United States, India and Asia-Pacific region. In 2021, he was listed in the Analytics India Magazine's 50 Most Influential AI Leaders in India. He holds a Bachelors in Engineering from BITS Pilani and an MBA from IIM Bangalore.

Mr. Leo Puri has been a member of our Board of Directors since October 2018, and serves as the lead independent director. Mr. Puri was the Managing Director of UTI Asset Management Co. Ltd. from August 2013 to August 2018. Mr. Puri served as the Chairman of JP Morgan Chase for South and South East Asia in 2020-2024. In his career of nearly four decades, he worked as Director with McKinsey and Company and as Managing Director with Warburg Pincus. Mr. Puri has worked in the United Kingdom, the United States and Asia. Since 1994, he has primarily worked in India. At McKinsey, he has advised leading financial institutions, conglomerates and investment institutions in strategy and operational issues. He has contributed to the development of knowledge and public policy through advice to regulators and government officials. At Warburg Pincus, he was responsible for leading and managing investments across industries in India. He also contributed to financial services investments in the international portfolio as a member of the global partnership. Mr. Puri is an independent director on the Board of Amadeus IT group based in Madrid, and is the independent chairman of Fortis Healthcare Ltd. He has served as an independent director on the boards of Tata Sons, Hindustan Unilever, and Infosys in the past. Mr. Puri has a Master's degree in P.P.E. from University of Oxford, and a Master's degree in Law from University of Cambridge.

Mr. Arun M. Kumar has been a member of our Board of Directors since August 2022. He is a Managing Partner at Celesta Capital, a leading deep technology venture capital firm that leverages synergies between leading centres of innovation in the United States and India to create globally impactful enterprises. In February 2022, Mr. Arun completed his five-year term as the Chairman and CEO of KPMG in India. In this role, he led a large organization of thousands of talented professionals engaged in providing assurance, tax, and advisory services, through a period of extraordinary organizational transformation and growth. He was a member of the global board of directors of KPMG as well as its Europe, Middle East and Africa (EMA) board. Mr. Arun previously served in President Obama's Administration as Assistant Secretary of Commerce for Global Markets and as Director General of the U.S. & Foreign Commercial Service (USFCS), under the leadership of Commerce Secretary Penny Pritzker. As the Administration's lead official to promote U.S. exports, foreign direct investment, and enhanced market access around the world, he led a team of 1,700 professionals in 78 countries and all 50 states of the United States. The Global Markets unit and USFCS saw substantial growth in coverage and impact during his tenure. During that time, Mr. Arun also had a special focus on the U.S.-India economic relationship, helping establish high level bilateral dialogues in areas ranging from innovation to infrastructure and working closely with the U.S. India CEO Forum. Prior to his nomination by President Obama, Mr. Arun was a partner at KPMG LLP in the United States and was a member of the Board of the firm. Based in Silicon Valley, he led KPMG's Management Consulting practice in the West. Before joining KPMG, he was a co-founder, CEO, and CFO of three technology companies in Silicon Valley; over the years, Mr. Arun has been a mentor to entrepreneurs in Silicon Valley and India. Mr. Arun is a member of the Council on Foreign Relations. Mr. Arun is an advisor to the Board of Directors of the U.S.-India Business Council. He serves on the board of Indiaspora, an organization that links accomplished and influential people of Indian origin in many countries to enhance the relationships between their country of residence and India. Mr. Arun serves as a director on the Board of our wholly owned U.S. subsidiary Dr. Reddy's Laboratories Inc. and serves as a Nominee Director on the Board of Agnikul Cosmos Private Limited. He is the author of The Global Trade Paradigm, published by HarperCollins in 2023. Mr. Arun received his master's degree from the MIT Sloan School of Management. He earned his undergraduate degree, in physics, as a National Science Talent Scholar, from the University of Kerala.

Mr. Sanjiv Mehta is the Executive Chairman of L Catterton India, a private equity enterprise, Board Member (Non-Executive) of Air India Ltd & Danone S.A., France and is the President Commissioner (Non-Executive Chairman) of PT Unilever TbK, Indonesia. Mr Mehta has been the Chairman/ CEO and Managing Director (2013-23) of Hindustan Unilever Limited (HUL) which is India's foremost fast-moving consumer goods company. During his 10 years at the helm of HUL, its market capitalization increased from $17 billion to $76 billion, making it the fifth most valuable company in India and the most valuable business for Unilever. Mr. Mehta was also the President of Unilever South Asia, having a combined turnover of $9 billion, and a member of 'Unilever Leadership Executive', the global executive board of the consumer goods giant. Mr. Mehta has been the CEO / Executive Chairman of Unilever Businesses in different parts of the world for 21 years from 2002-23. He was Chairman and Managing Director of Unilever Bangladesh Limited (2002-06), Chairman and CEO of Unilever Philippines Inc. (2007-08), Chairman of Unilever - North Africa and Middle East (2008-13) and took over India and South Asia responsibilities from 2013. In each of these roles he left his imprint by turning around businesses in trouble, winning major competitive battles and accelerating growth and margins. Mr. Mehta has done his Bachelor's in Commerce, Chartered Accountancy and has also completed his Advanced Management Program (Harvard Business School). Mr. Mehta has been the President of India's oldest and largest trade body FICCI (Federation of Indian Chambers of Commerce and Industry) during 2021-22, is a member of the South Asia Advisory Board of Harvard Business School and is Chairman Emeritus of 'Vikaasa', a coalition of top Indian and multi-national companies. During the period when Mr. Mehta was heading HUL it won several recognitions, including the prestigious The Economic Times 'Company of the Year' & 'Corporate Citizen of the Year' awards, Business Standard's 'Company of the year' award, the 'Best Governed Company' award by the Asian Centre for Corporate Governance and Sustainability and the 'Outstanding Company of the Year' award at CNBC-TV18's India Business Leader Awards (IBLA). Forbes rated HUL as the most innovative company in India and the 8th most innovative company in the world. Aon Hewitt in a global study rated HUL as the 3rd best company globally for building leaders. Mr. Mehta was conferred the honorary degree of 'Doctor of Philosophy in Business Management' by Xavier University (Xavier Institute of Management) in 2019. He has received several personal recognitions including the 'Best CEO Multinational' by Forbes, the 'Management Man of the Year' by Bombay Management Association, the 'CA Business Leader' by The Institute of Chartered Accountants of India, the 'Best Transformational Leader' by the Asian Centre for Corporate Governance and Sustainability, the 'Business Leader of the Year' by The Economic Times, 'Best CEO' Award from Business Today, Pralhad P. Chhabria Memorial Global Award, the 'JRD Tata Corporate Leadership award' by the All India Management Association, the 'Sir Jehangir Ghandy Medal' by Xavier School of Management (XLRI), Jamshedpur, 'IMPACT Person of the Year' by exchange4media group (Business World), 'Lifetime Achievement Award' by CEO's Association for Inclusive India -SKOCH Group, 'CEO of the year' by Business Standard and 'Best of the Best CEO's' by Fortune. He has also been inducted into the 'Hall of Fame' by The Institute of Chartered Accountants of India.

Dr. K.P. Krishnan served in the Indian Administrative Service (IAS) for 37 years and retired on 12/31/2019. In his IAS career, he served in various positions in the Government of Karnataka, in the Government of India and at the World Bank. Besides field positions like District Collector Mangalore, he served in Government of Karnataka departments dealing with agriculture, co-operatives and marketing, urban development and infrastructure, commercial taxes and finance. His key roles in the Government of India include: 1. Secretary, Ministry of Skill Development and Entrepreneurship (2/1/2017 to 12/31/2019); 2. Special/Additional Secretary, Department of Land Resources, Ministry of Rural Development (2014-2017); 3. Additional Secretary, Department of Economic Affairs, Ministry of Finance (2013- 2014); 4. Secretary, Prime Minister's Economic Advisory Council (2010- 2012); and 5. Joint Secretary, Department of Economic Affairs, Ministry of Finance (2005-2010). In these positions, he served on the boards of corporations, banks as well as boards of statutory regulatory authorities. In parallel with his government career, Dr. Krishnan has been a strong researcher and academic. Besides being visiting faculty at IIM Bangalore, ISB and Ashoka University, he held the prestigious Bok Visiting Professorship of Regulation at the University of Pennsylvania Law School in 2012-13. From 8/7/2020 until 12/31/2021, he served as the IEPF Chair Professor of Economics at the National Council of Applied Economic Research (NAER) New Delhi. From Feb, 2022 to Feb., 2024, he also served as Honorary Research Professor at the Centre for Policy Research (CPR) New Delhi and at present he is Distinguished Fellow at the Isaac Centre for Public Policy, Ashoka University. At present, he is an independent Director/advisory board member of both for-profit companies and non-profit organizations, including Tata Consumer Products Ltd., Dr. Reddy's Laboratories Ltd., Shriram Capital Pvt. Limited, ASREC India Ltd, Helios Trustee Private Ltd., CUPDF, IIHS, Razorpay Advisory Board and Sanmar Group Corporate Board. Dr. Krishnan was educated in Economics at St. Stephens College and Law at the Campus Law Centre University of Delhi. He joined IIM Bangalore in 1999 and was awarded FPM (Ph.D) in Economics in the 2003 graduation ceremony.

Mr. M.S. Madhu Sundar was elevated as Global Head of Quality and Pharmacovigilance and was also inducted as a member of our Management Council, effective from April 1, 2026. Mr. Madhu Sundar joined the company in October 2017 as the site head of the Pydibimavaram oral solid dose (OSD) cluster and has assumed responsibilities of increasing significance since. His last role was Head of Manufacturing for its OSD sites of the manufacturing network. His professional experience of 28 years span across manufacturing, Research & Development, Quality and Regulatory affairs between API and dosage forms. Among his professional interests are exploring the latest trends of digital in manufacturing, process analytical technologies and Lean. Mr. Madhu is a post graduate in Chemistry and a M. Tech in Chemical Analysis from IIT Delhi.